TAVNEOS remains available. For questions about the recent updates on TAVNEOS® and what this means for you, please review Amgen's Statement
This link is updated regularly to keep the community informed on the latest information.
An established safety profile from a targeted therapy through 52 weeks2
Most common adverse reactions reported in ≥5% of patients and higher in the TAVNEOS® arm vs the Active Control arm in a phase 3 trial2
| Adverse reaction | TAVNEOS® arm (N = 166), n (%) | Active Control arm (N = 164), n (%) |
|---|---|---|
| Nausea | 39 (23.5) | 34 (20.7) |
| Headache | 34 (20.5) | 23 (14.0) |
| Hypertension | 30 (18.1) | 29 (17.7) |
| Diarrhea | 25 (15.1) | 24 (14.6) |
| Vomiting | 25 (15.1) | 21 (12.8) |
| Rash | 19 (11.4) | 13 (7.9) |
| Fatigue | 17 (10.2) | 15 (9.1) |
| Upper abdominal pain | 11 (6.6) | 10 (6.1) |
| Dizziness | 11 (6.6) | 10 (6.1) |
| Blood creatinine increased | 10 (6.0) | 8 (4.9) |
| Paresthesia | 9 (5.4) | 7 (4.3) |
The incidence of infection was 68.1% (n = 113) of patients in the TAVNEOS® arm vs 75.6% (n = 124) of patients in the Active Control arm1
- TAVNEOS® arm: 233 total events; serious infections occurred in 13.3% (n = 22) of patients, with 25 total events
- Active Control arm: 291 total events; serious infections occurred in 15.2% (n = 25) of patients, with 31 total events
Hepatotoxicity
ADVOCATE trial experience2
- Patients with hepatic-related adverse reactions, including hepatobiliary adverse reactions and liver enzyme abnormalities: 22 (13.3%) in the TAVNEOS® arm vs 19 (11.6%) in the Active Control arm
- Serious hepatic-related adverse reactions: 9 (5.4%) in the TAVNEOS® arm vs 6 (3.7%) in the Active Control arm
- Study medication paused or permanently discontinued: 9 (5.4%) in the TAVNEOS® arm vs 5 (3.0%) in the Active Control arm
Postmarketing experience2
- Vanishing bile duct syndrome (VBDS) as a consequence of liver injury, including cases with a fatal outcome, has been reported
- Cases occurred predominantly in Japan in patients 65 years and older, but VBDS may affect patients of any age or ethnicity who are receiving TAVNEOS®
Monitoring and guidance2
- Obtain liver test panel (serum alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase [ALP], and total bilirubin) before initiating TAVNEOS®, every 4 weeks after start of therapy for 6 months, and as clinically indicated thereafter
- Consider more frequent lab testing for patients of Japanese descent: every 2 weeks after start of therapy for the first 3 months, followed by lab testing every 4 weeks for the next 3 months, and as clinically indicated thereafter
- If a patient receiving treatment with TAVNEOS® presents with an elevation in ALT or AST to >3 times the upper limit of normal (ULN), evaluate promptly and consider pausing treatment as clinically indicated
- Discontinue TAVNEOS® until TAVNEOS®-induced liver injury is ruled out if:
- AST or ALT is >5 times the ULN, or
- ALT or AST is >3 times the ULN with total bilirubin >2 times the ULN, or
- alkaline phosphatase is ≥2 times the ULN, or
- the patient has clinical symptoms such as jaundice or pruritus
- Immediately and permanently discontinue TAVNEOS® if VBDS is suspected
- TAVNEOS® is not recommended for patients with active, untreated and/or uncontrolled chronic liver disease (eg, chronic active hepatitis B, untreated hepatitis C, uncontrolled autoimmune hepatitis) and cirrhosis. Consider the risk and benefit before administering TAVNEOS® to a patient with liver disease. Monitor patients closely for hepatic adverse reactions
AE = adverse event; GPA = granulomatosis with polyangiitis; MPA = microscopic polyangiitis.